Medicine and Dentistry
Lung Adenocarcinoma
100%
Oncogene
100%
Virus Oncogene
100%
Exon
100%
Phosphoinositide 3-Kinase
100%
Anaplastic Lymphoma Kinase
100%
Targeted Therapy
66%
Epidermal Growth Factor Receptor
66%
Connective Tissue Cancer
66%
Adenocarcinoma
33%
Clinical Trial
33%
Neoplasm
33%
Cancer
33%
Enzyme Active Site
33%
Carcinogenesis
33%
Medical Record
33%
Epidermal Growth Factor Receptor 2
33%
Gamma Urogastrone
33%
Ras Signaling
33%
Ganglioneuroblastoma
33%
Erlotinib
33%
Polypeptide
33%
Signaling Protein
33%
Mitogen Activated Protein Kinase Kinase 1
33%
Epidermal Growth Factor Receptor 3
33%
Crizotinib
33%
Lung
33%
Thymus Cancer
33%
Protein Kinase B
33%
Keyphrases
Lung Adenocarcinoma
100%
PIK3CA
100%
Mutation Profiling
100%
Oncogene mutation
100%
PIK3CA mutation
80%
Epidermal Growth Factor Receptor
60%
Phosphoinositide 3-kinase (PI3K)
60%
MEK1
40%
Targeted Therapy
40%
Oncogene
40%
Anaplastic Lymphoma Kinase
40%
Viral Oncogenes
40%
Clinical Trials
20%
AKT1
20%
Sarcoma
20%
Malignancy
20%
Catalytic Subunit
20%
Tumorigenesis
20%
Clinical Data
20%
Working Diagnosis
20%
Medical Records
20%
Mitogen-activated Protein Kinase
20%
Patient Characteristics
20%
Signaling Molecules
20%
Never-smokers
20%
Ligand-binding Domain
20%
Human Epidermal Growth Factor Receptor 2 (HER2)
20%
Exon 20
20%
Thymoma
20%
Driver mutations
20%
Neuroblastoma
20%
Mitogenic Signaling
20%
Erlotinib
20%
Exon 19 Deletion
20%
H1047R
20%
Recurrent mutation
20%
Tumor Specimens
20%
Dual Specificity
20%
V-raf murine Sarcoma Viral Oncogene Homolog B1
20%
Anaplastic Lymphoma Kinase Rearrangement
20%
Crizotinib
20%
Treatment Resistance
20%
Exon 9
20%
Alpha Polypeptide
20%
P110α
20%
Biochemistry, Genetics and Molecular Biology
Oncogene
100%
Epidermal Growth Factor Receptor
100%
Exon
75%
Phosphoinositide 3-Kinase
75%
Anaplastic Lymphoma Kinase
75%
KRAS
75%
Virus Oncogene
75%
Targeted Therapy
50%
Clinical Trial
25%
Carcinogenesis
25%
Enzyme Active Site
25%
Genotyping
25%
AKT1
25%
Murine
25%
Signaling Protein
25%
Binding Domain
25%
Medical Record
25%
Erlotinib
25%
Mitogen-Activated Protein Kinase Kinase
25%
Protein Kinase B
25%
Crizotinib
25%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphatidylinositol 3 Kinase
100%
Lung Adenocarcinoma
100%
Anaplastic Lymphoma Kinase
100%
Epidermal Growth Factor Receptor
66%
Connective Tissue Cancer
66%
Neoplasm
33%
Clinical Trial
33%
Carcinogenesis
33%
Adenocarcinoma
33%
Epidermal Growth Factor Receptor 2
33%
Gamma Urogastrone
33%
Murine
33%
Erlotinib
33%
Polypeptide
33%
Neuroblastoma
33%
Mitogen Activated Protein Kinase Kinase 1
33%
Epidermal Growth Factor Receptor 3
33%
Crizotinib
33%
Thymus Cancer
33%